Saturday 17 October 2026
Export URGN’s income statement to Excel — free account
Urogen Pharma
URGN Healthcare Biotechnology
Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
34.56
2.05
−5.60%
Follow URGN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | 6 | 4 | 3 | 3 | 4 | 2 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(5.16) | (2.85) | (4.09) | (5.94) | (5.54) | 2.69 | 16.01 | 27.15 | 30.27 | — |
P/S ratio |
10.26 | 5.05 | 5.30 | 3.06 | 4.42 | 33.21 | 1,030.15 | 601.39 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.35 |
Altman Z″-Score (non-manufacturers) |
(15.59) | (6.22) | (10.10) | (13.13) | (12.78) | (7.50) | 5.45 | 3.77 | 12.27 | 4.30 |
Beneish M-Score |
(1.42) | (2.82) | (2.80) | (4.04) | (1.27) | — | — | — | — | — |
P/Operating CF |
(29.40) | (33.53) | (33.75) | (9.06) | (10.59) | (18.48) | (26.35) | (65.96) | (63.01) | (11.75) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 25.26 | 4.07 | 3.80 | 7.53 | 5.48 | 1.98 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 25.26 | 4.07 | 3.80 | 7.53 | 5.48 | 1.98 |
EV/Sales |
10.30 | 3.77 | 4.83 | 3.01 | 2.55 | 24.60 | 812.12 | 511.34 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(6.96) | (3.52) | (5.23) | (2.21) | (1.44) | (2.75) | (7.60) | (15.45) | (31.59) | 9.94 |
EV/FCF |
(6.95) | (3.51) | (5.22) | (2.21) | (1.43) | (2.71) | (7.57) | (15.22) | (30.72) | 21.38 |
Quick Ratio |
3.34 | 5.62 | 4.91 | 4.75 | 4.56 | 5.15 | 7.58 | 7.54 | 10.40 | 6.87 |
Current Ratio |
4.01 | 6.01 | 5.42 | 5.39 | 5.11 | 5.39 | 7.63 | 7.59 | 10.59 | 7.03 |
Net Debt/EBITDA |
0.00 | 1.17 | 0.60 | 0.04 | 0.99 | 0.81 | 1.32 | 1.32 | 3.71 | (21.22) |
Debt/Assets |
60.97% | 42.61% | 55.27% | 71.92% | 0.33% | 1.23% | 1.29% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.16) | (13.83) | (1.51) | (1.09) | 0.05 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.45 | 0.39 | 0.53 | 0.50 | 0.40 | 0.07 | 0.00 | 0.01 | 0.17 | 0.83 |
Operating CF/Net income |
1.06 | 0.76 | 0.75 | 0.80 | 0.77 | 0.82 | 0.68 | 0.49 | 0.48 | (2.16) |
Capex/Depreciation |
0.18 | 0.12 | 0.84 | (0.60) | (0.58) | (1.42) | 1.18 | (1.34) | (1.31) | (3.26) |
Interest Coverage |
(8.14) | (7.73) | (4.45) | (9.37) | (252.85) | (63.82) | (23.72) | (41.23) | (643.55) | 0.29 |
| 268.63% | 342.83% | 132.29% | 271.24% | (211.55%) | (92.88%) | (77.77%) | (95.40%) | (47.16%) | (11.92%) | |
| (63.14%) | (54.68%) | (65.14%) | (85.98%) | (91.68%) | (79.22%) | (68.73%) | (84.48%) | (40.57%) | (9.15%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (193.80%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(109.45%) | (54.96%) | (73.74%) | (103.29%) | (117.92%) | (133.52%) | (80.80%) | (84.32%) | (29.31%) | (9.88%) |
Average Days of Receivables |
109.98 | 81.97 | 68.15 | 72.05 | 89.02 | 218.00 | 0.00 | 0.00 | 0.00 | 1.73 |
Research and Development Expense of Revenue |
61.12% | 63.21% | 55.15% | 82.21% | 99.17% | 400.97% | 273,872.22% | 3,274.29% | 229.19% | 58.68% |
Selling, General and Administrative Expense of Revenue |
141.27% | 134.02% | 112.77% | 128.72% | 182.21% | 764.63% | 334,438.89% | 3,508.07% | 108.00% | 36.61% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10.89% | 14.50% | 11.30% | 16.44% | 48.11% | 237.52% | 166,483.33% | 2,716.49% | 77.22% | 11.22% |
Graham Net Nets |
(0.11) | (0.04) | (0.17) | (0.49) | 0.01 | 0.23 | 0.18 | 0.13 | 0.18 | 0.59 |
Graham Number |
12.56 | 3.86 | 13.78 | 20.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(13.66%) | (30.33%) | (24.52%) | (55.32%) | (52.16%) | (32.85%) | (15.31%) | (11.05%) | (7.61%) | (43.78%) |
Free Cash Flow Yield |
(14.44%) | (21.27%) | (17.46%) | (44.56%) | (40.30%) | (27.29%) | (10.41%) | (5.59%) | (2.62%) | 2.07% |
Revenue per Share |
2.28 | 2.11 | 2.87 | 2.82 | 2.15 | 0.54 | 0.00 | 0.07 | 0.84 | 7.60 |
Operating CF per Share |
(3.38) | (2.26) | (2.65) | (3.84) | (3.80) | (4.86) | (3.46) | (2.37) | (0.98) | 1.82 |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | (0.03) | (0.06) | (0.02) | (0.04) | (0.03) | (0.30) |
Free Cash Flow per Share |
(3.38) | (2.26) | (2.66) | (3.85) | (3.83) | (4.92) | (3.48) | (2.41) | (1.01) | 1.52 |
Cash per Share |
2.53 | 5.55 | 4.78 | 4.42 | 4.04 | 4.74 | 7.19 | 6.45 | 7.53 | 9.31 |
Shareholders Equity per Share |
(2.19) | (0.21) | (2.26) | (3.92) | 0.38 | 4.42 | 8.78 | 5.72 | 7.05 | 7.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.19) | (0.21) | (2.26) | (3.92) | 0.38 | 4.42 | 8.78 | 5.72 | 7.05 | 7.07 |
Free Cash Flow |
(162.73) | (97.06) | (76.57) | (87.81) | (85.64) | (107.10) | (71.34) | (37.89) | (9.84) | 3.49 |
Working Capital |
139.61 | 230.19 | 137.97 | 104.99 | 92.01 | 94.18 | 129.15 | 88.78 | 67.44 | 18.90 |
Capital Expenditures |
(0.29) | (0.29) | (0.19) | (0.25) | (0.75) | (1.21) | (0.32) | (0.56) | (0.27) | (0.69) |
Net Current Asset Value |
(119.90) | (18.38) | (74.34) | (96.07) | 3.06 | 89.97 | 126.55 | 88.78 | 67.44 | 15.29 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.10 | 18.06 | 0.50 | 0.03 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(2.46) | (3.91) | (0.34) | 0.33 | 0.66 | 0.42 | (0.28) | 0.44 | 0.26 | 0.29 |
Cash ROIC |
(117.46%) | (27.68%) | (44.74%) | (80.60%) | (86.36%) | (53.26%) | (21.59%) | (19.77%) | (6.94%) | 9.25% |
Accounts Receivable Turnover |
4.11 | 5.06 | 5.88 | 5.27 | 5.12 | 3.31 | 0.00 | 0.00 | 0.00 | 4.92 |
Accounts Payable Turnover |
0.45 | 0.40 | 0.65 | 0.63 | 0.47 | 0.10 | 0.00 | 0.28 | 0.19 | 0.02 |
Inventory Turnover |
0.97 | 1.19 | 1.87 | 1.67 | 1.52 | 0.89 | — | 5.71 | 2.85 | 0.13 |
Average Days of Payables |
812.78 | 1,127.39 | 644.84 | 590.51 | 856.55 | 3,625.76 | 0.00 | 1,728.84 | 2,697.96 | 24,507.14 |
Days of Inventory on Hand |
482.80 | 379.22 | 221.20 | 206.25 | 342.00 | 710.47 | — | 63.97 | 192.23 | 1,368.75 |
Average Receivables |
26.69 | 17.87 | 14.07 | 12.21 | 9.38 | 3.57 | — | — | — | 3.57 |
Average Payables |
27.57 | 21.98 | 14.46 | 12.24 | 11.06 | 10.60 | 9.86 | 6.49 | 3.16 | 1.80 |
Average Inventory |
12.85 | 7.45 | 5.00 | 4.58 | 3.40 | 1.14 | — | 0.32 | 0.21 | 0.21 |
Average Assets |
243.08 | 232.01 | 156.97 | 127.68 | 120.88 | 162.20 | 152.97 | 89.55 | 49.30 | 21.22 |
Average Common Equity |
(57.14) | (37.01) | (77.29) | (40.47) | 52.38 | 138.33 | 135.20 | 79.30 | 42.40 | 16.29 |
Columns are period end dates